Completion of USFDA Inspection at the Company''s Formulation Facility at Alathur

September 11, 2026 The National Stock Exchange of India Limited BSE Limited Exchange Plaza, Bandra-Kurla Complex Phiroze Jeejeebhoy Towers, Bandra (E) Mumbai - 400 051 Dalal Street, Mumbai – 400 001 Scrip code: STAR Scrip code: 532531 Dear Madam/ Sir, Reg: Disclosure under Regulation 30 of SEBI Listing Regulations Sub: Completion of USFDA Inspection at the Company’s Formulations Facility at Alathur We hereby notify that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Company's Formulations Facility at Alathur, Chennai during the period from September 2, 2026 to September 11, 2026. At the conclusion of the inspection, the USFDA has issued a Form 483 with three observations. Company will respond to these observations to USFDA within the stipulated time. We will keep the stock exchanges informed if there is any further update in this matter. Please take the above information on record. Thanks & Regards, For Strides Pharma Science Limited, Manjula Ramamurthy Company Secretary ICSI Membership No. A30515 Strides Pharma Science Limited CIN: L24230MH1990PLC057062 Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India |Tel: +91 80 6784 0000 Regd. Off: ‘Cyber One’, Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924/3199 corpcomm@strides.com; www.strides.com